Factors Associated with Short-Term Local Recurrence of Liver Cancer after Percutaneous Ablation Using Irreversible Electroporation: A Prospective Single-Center Study

Niessen, Christoph; Igl, Juliane; Pregler, Benedikt; Beyer, Lukas Philipp; Noeva, Ekaterina; Dollinger, Marco; Schreyer, A. G.; Jung, Ernst Michael; Stroszczynski, Christian; Wiggermann, Philipp

doi:10.1016/j.jvir.2015.02.001

Cited by 59 publications

(47 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that HCC had distinctly better therapeutic results compared with liver metastases43. Likewise, an earlier study by our working group investigated early recurrence after percutaneous therapy using IRE and found that HCC tumors exhibited fewer earlier recurrences compared with other diagnoses40. In our current study, patients with HCC demonstrated a longer survival time (26.8 months) compared with those with liver metastases, yet this difference was not comparatively significant.…”

Section: Discussionsupporting

confidence: 50%

“…Compared with thermal ablation, perivascular tumor ablation with IRE appears to result in less frequent recurrence, indicating that the effectiveness of IRE is not influenced by the heat sink effect40. The current state of information does not permit a final statement on IRE.…”

Section: Discussionmentioning

confidence: 92%

“…The success rate is up to 90% but decreases rapidly in relation to tumor size41. Our previous study analyzing the risk factors for an early local recurrence demonstrated that similar to conventional (thermal) ablation techniques, a larger tumor diameter represents an independent risk factor for local recurrence40. Based on a study of 44 patients, Cannon et al .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors

Niessen

Thumann

Beyer

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Aim of this retrospective analysis was to evaluate the survival times after percutaneous irreversible electroporation (IRE) in inoperable liver tumors not amenable to thermal ablation. 71 patients (14 females, 57 males, median age 63.5 ± 10.8 years) with 103 liver tumors were treated in 83 interventions using IRE (NanoKnife® system). The median tumor short-axis diameter was 1.9 cm (minimum 0.4 cm, maximum 4.5 cm). 35 patients had primary liver tumors and 36 patients had liver metastases. The Kaplan-Meier method was employed to calculate the survival rates, and the different groups were compared using multivariate log-rank and Wilcoxon tests. The overall median survival time was 26.3 months; the median survival of patients with primary land secondary liver cancer did not significantly differ (26.8 vs. 19.9 months; p = 0.41). Patients with a tumor diameter >3 cm (p < 0.001) or more than 2 lesions (p < 0.005) died significantly earlier than patients with smaller or fewer tumors. Patients with hepatocellular carcinoma and Child-Pugh class B or C cirrhosis died significantly earlier than patients with Child-Pugh class A (p < 0.05). Patients with very early stage HCC survived significantly longer than patients with early stage HCC with a median survival of 22.3 vs. 13.7 months (p < 0.05).

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors

Niessen

Thumann

Beyer

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Particularly important to the treatment of HCC are the numerous studies showing that properly selected patients with cirrhosis can tolerate IRE 19,21,23,25–27. Although some studies limited analysis to Child–Pugh class A and B,21,26,27 many studies do not discuss specifics of patient selection in the setting of cirrhosis.…”

Section: Ire For Hccmentioning

confidence: 99%

Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

Zimmerman¹,

Grand

Charpentier³

2017

JHC

View full text Add to dashboard Cite

Irreversible electroporation (IRE) is a novel form of tissue ablation that uses high-current electrical pulses to induce pore formation of the cell lipid bilayer, leading to cell death. The safety of IRE for ablation of hepatocellular carcinoma (HCC) has been established. Outcome data for ablation of HCC by IRE are limited, but early results are encouraging and suggest equivalency to the outcomes obtained for thermal ablation for appropriately selected, small (<3 cm) tumors. Long-term oncologic efficacy and histopathologic response data have not been published, and therefore, application of IRE for the treatment of HCC should still be viewed with caution.

show abstract

“…A total of 43 patients (RFA 22, IRE 21) were included, and post-procedural pain was comparable in both groups [77] . In another recent trial, Niessen et al [78] evaluated the risk factors associated with short-term local recurrence after IRE. Twenty-five patients with 48 malignant liver lesions (HCC = 22; cholangiocarcinoma = 6; metastases = 20) underwent IRE.…”

Section: Figure 2 Axial Computed Tomography Images Before and After Rmentioning

confidence: 99%

Locoregional treatment for hepatocellular carcinoma: The best is yet to come

Kalra

Gupta

Chawla

et al. 2015

WJR

View full text Add to dashboard Cite

Factors Associated with Short-Term Local Recurrence of Liver Cancer after Percutaneous Ablation Using Irreversible Electroporation: A Prospective Single-Center Study

Cited by 59 publications

References 37 publications

Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors

Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors

Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

Locoregional treatment for hepatocellular carcinoma: The best is yet to come

Contact Info

Product

Resources

About